$PTGX
Protagonist Therapeutics, Inc

2024 Q4 Form 10-Q Financial Statement

#000155837024014888 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $4.675M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.16M $7.660M
YoY Change 32.61% 11.0%
% of Gross Profit
Research & Development $35.97M $30.66M
YoY Change 17.3% 20.71%
% of Gross Profit
Depreciation & Amortization $231.0K $240.0K
YoY Change -3.75% -11.11%
% of Gross Profit
Operating Expenses $46.13M $38.33M
YoY Change 20.36% 18.65%
Operating Profit -$41.45M -$38.33M
YoY Change 8.16% 18.65%
Interest Expense $7.682M $4.250M
YoY Change 80.75% 267.33%
% of Operating Profit
Other Income/Expense, Net $141.0K -$31.00K
YoY Change -554.84% -63.95%
Pretax Income -$33.63M -$34.11M
YoY Change -1.41% 9.21%
Income Tax -$400.0K $0.00
% Of Pretax Income
Net Earnings -$33.21M -$34.11M
YoY Change -2.62% 9.2%
Net Earnings / Revenue -710.37%
Basic Earnings Per Share -$0.54 -$0.58
Diluted Earnings Per Share -$0.54 -$0.58
COMMON SHARES
Basic Shares Outstanding 59.60M 58.90M 57.53M
Diluted Shares Outstanding 61.77M 59.18M

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $468.7M $320.8M
YoY Change 46.11% 19.95%
Cash & Equivalents $131.1M $230.5M
Short-Term Investments $337.6M $90.20M
Other Short-Term Assets $2.669M $65.00K
YoY Change 4006.15% -99.24%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $476.8M $324.9M
YoY Change 46.75% 17.45%
LONG-TERM ASSETS
Property, Plant & Equipment $2.468M $1.421M
YoY Change 73.68% -20.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $114.6M $2.000M
YoY Change 5628.0%
Other Assets $225.0K $200.0K
YoY Change 12.5% -11.11%
Total Long-Term Assets $127.1M $5.135M
YoY Change 2374.94% -7.59%
TOTAL ASSETS
Total Short-Term Assets $476.8M $324.9M
Total Long-Term Assets $127.1M $5.135M
Total Assets $603.9M $330.0M
YoY Change 82.98% 16.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.049M $1.252M
YoY Change 143.53% -73.45%
Accrued Expenses $20.74M $24.81M
YoY Change -16.41% -16.11%
Deferred Revenue $3.000K
YoY Change -90.63%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.58M $27.87M
YoY Change 59.97% -24.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $27.36M $0.00
YoY Change -100.0%
Total Long-Term Liabilities $27.36M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.58M $27.87M
Total Long-Term Liabilities $27.36M $0.00
Total Liabilities $71.94M $27.87M
YoY Change 158.16% -27.73%
SHAREHOLDERS EQUITY
Retained Earnings -$472.2M -$643.0M
YoY Change -26.56% 27.93%
Common Stock $1.003B $945.4M
YoY Change 6.07% 26.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $531.9M $302.1M
YoY Change
Total Liabilities & Shareholders Equity $603.9M $330.0M
YoY Change 82.98% 16.95%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$33.21M -$34.11M
YoY Change -2.62% 9.2%
Depreciation, Depletion And Amortization $231.0K $240.0K
YoY Change -3.75% -11.11%
Cash From Operating Activities -$27.86M -$26.61M
YoY Change 4.71% 5.59%
INVESTING ACTIVITIES
Capital Expenditures $775.0K $400.0K
YoY Change 93.75% -346.91%
Acquisitions
YoY Change
Other Investing Activities -$207.9M -$13.15M
YoY Change 1481.25% -122.89%
Cash From Investing Activities -$208.7M -$13.56M
YoY Change 1439.16% -123.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.05M 35.31M
YoY Change -65.87% 5092.65%
NET CHANGE
Cash From Operating Activities -27.86M -26.61M
Cash From Investing Activities -208.7M -13.56M
Cash From Financing Activities 12.05M 35.31M
Net Change In Cash -224.5M -4.860M
YoY Change 4519.79% -114.84%
FREE CASH FLOW
Cash From Operating Activities -$27.86M -$26.61M
Capital Expenditures $775.0K $400.0K
Free Cash Flow -$28.64M -$27.01M
YoY Change 6.03% 7.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
CY2023Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
CY2024Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57708613
dei Entity Central Index Key
EntityCentralIndexKey
0001377121
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59521903
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37852
dei Entity Registrant Name
EntityRegistrantName
PROTAGONIST THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0505495
dei Entity Address Address Line1
EntityAddressAddressLine1
7707 Gateway Boulevard, Suite 140
dei Entity Address City Or Town
EntityAddressCityOrTown
Newark
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94560-1160
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
474-0170
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
PTGX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59598018
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
131121000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
186727000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
337600000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
154890000
CY2023Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
10000000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8048000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3960000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
476769000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
355577000
CY2024Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
114560000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2468000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1195000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
225000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
225000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9835000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
954000
CY2024Q3 us-gaap Assets
Assets
603857000
CY2023Q4 us-gaap Assets
Assets
357951000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3049000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
772000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3000
CY2024Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
20739000
CY2023Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
19358000
CY2024Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
19696000
CY2024Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1049000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
45000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1141000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
44578000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21274000
CY2024Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
16509000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10855000
CY2024Q3 us-gaap Liabilities
Liabilities
71942000
CY2023Q4 us-gaap Liabilities
Liabilities
21274000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59521903
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57708613
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1002774000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
952491000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1336000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-105000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-472196000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-615710000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
531915000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
336677000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
603857000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
357951000
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4675000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
263795000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35970000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30664000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
103224000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91262000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10158000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7662000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34508000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25439000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
46128000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
38326000
us-gaap Operating Expenses
OperatingExpenses
137732000
us-gaap Operating Expenses
OperatingExpenses
116701000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-41453000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-38326000
us-gaap Operating Income Loss
OperatingIncomeLoss
126063000
us-gaap Operating Income Loss
OperatingIncomeLoss
-116701000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
7682000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4252000
us-gaap Investment Income Interest
InvestmentIncomeInterest
19462000
us-gaap Investment Income Interest
InvestmentIncomeInterest
10656000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
141000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-31000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
219000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-245000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33630000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34105000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
145744000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-106290000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-420000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2230000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-33210000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-34105000
us-gaap Net Income Loss
NetIncomeLoss
143514000
us-gaap Net Income Loss
NetIncomeLoss
-106290000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.91
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.91
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61767934
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59182899
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61311310
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55542543
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61767934
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59182899
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64611941
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55542543
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-33210000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-34105000
us-gaap Net Income Loss
NetIncomeLoss
143514000
us-gaap Net Income Loss
NetIncomeLoss
-106290000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1585000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
28000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1441000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
194000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31625000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34077000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
144955000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-106101000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
541324000
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
12051000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10165000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1585000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-33210000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
531915000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
294068000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
33813000
CY2023Q3 ptgx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
559000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1021000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6765000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
28000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-34105000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
302149000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
336677000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
22422000
ptgx Shares Withheld For Net Settlements Of Tax Withholding Upon Vesting Of Restricted Stock Units
SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits
600000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28461000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1441000
us-gaap Net Income Loss
NetIncomeLoss
143514000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
531915000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
215608000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
33813000
ptgx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
559000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4255000
ptgx Shares Withheld For Net Settlements Of Tax Withholding Upon Vesting Of Restricted Stock Units
SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits
769000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22692000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
189000
us-gaap Net Income Loss
NetIncomeLoss
-106290000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
302149000
us-gaap Profit Loss
ProfitLoss
143514000
us-gaap Profit Loss
ProfitLoss
-106290000
us-gaap Share Based Compensation
ShareBasedCompensation
28461000
us-gaap Share Based Compensation
ShareBasedCompensation
22692000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1651000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1751000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
708000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
729000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
6115000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3221000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
194000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-10000000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-10000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4088000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1582000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2272000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2271000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-3000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-66000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1061000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-259000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
1049000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
36205000
us-gaap Operating Lease Payments
OperatingLeasePayments
1385000
us-gaap Operating Lease Payments
OperatingLeasePayments
2047000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
213330000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-87196000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
507293000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
93077000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
217580000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
115696000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1045000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
590000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-290758000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
22029000
ptgx Proceeds From Exercise Of Warrants In Exchange For Issuance Of Pre Funded Warrants
ProceedsFromExerciseOfWarrantsInExchangeForIssuanceOfPreFundedWarrants
33813000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
559000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
22422000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4255000
ptgx Shares Withheld For Net Settlement Of Tax Withholding Upon Vesting Of Restricted Stock Units
SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits
600000
ptgx Shares Withheld For Net Settlement Of Tax Withholding Upon Vesting Of Restricted Stock Units
SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits
769000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
107790000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
24302000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21822000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
169950000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-55606000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
104783000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
186952000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125969000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
131346000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
230752000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10511000
ptgx Leasehold Improvements Under Improvement Allowance
LeaseholdImprovementsUnderImprovementAllowance
613000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
325000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 ptgx Cash Cash Equivalents And Marketable Securities Carrying Value
CashCashEquivalentsAndMarketableSecuritiesCarryingValue
583300000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-472200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development activities, stock-based compensation, income taxes, marketable securities and leases. Estimates related to revenue recognition include assumptions used to determine standalone selling price utilized to allocate the transaction price between distinct performance obligations, assumptions used to recognize revenue over time for certain performance obligations for which a cost-based input method is used as the measure of progress and estimates of whether contingent consideration should be included in the transaction price at each reporting period. Management bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. Actual results may differ materially from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There has been uncertainty and disruption in the global economy and financial markets due to a number of factors, including geopolitical instability, inflationary pressures, high interest rates, a recessionary environment, domestic and global monetary and fiscal policy and other factors. The Company has taken into consideration any known impacts in its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the filing date of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.</p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
131121000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
230527000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
225000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
225000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
131346000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
230752000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10165000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6765000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28461000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22692000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36200000
CY2024Q3 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
4700000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
0
CY2023Q3 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
0
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
0
CY2024Q3 ptgx Cash Equivalents And Marketable Securities Amortized Cost
CashEquivalentsAndMarketableSecuritiesAmortizedCost
574011000
CY2024Q3 ptgx Cash Equivalents And Marketable Securities Gross Unrealized Gain
CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
1504000
CY2024Q3 ptgx Cash Equivalents And Marketable Securities Gross Unrealized Loss
CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
57000
CY2024Q3 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
575458000
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
123298000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
337600000
CY2024Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
114560000
CY2024Q3 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
575458000
CY2023Q4 ptgx Cash Equivalents And Marketable Securities Amortized Cost
CashEquivalentsAndMarketableSecuritiesAmortizedCost
315263000
CY2023Q4 ptgx Cash Equivalents And Marketable Securities Gross Unrealized Gain
CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
74000
CY2023Q4 ptgx Cash Equivalents And Marketable Securities Gross Unrealized Loss
CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
68000
CY2023Q4 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
315269000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
160379000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
154890000
CY2023Q4 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
315269000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
337600000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
154900000
ptgx Current Contractual Maturities Maximum Period
CurrentContractualMaturitiesMaximumPeriod
P1Y
CY2023 ptgx Current Contractual Maturities Maximum Period
CurrentContractualMaturitiesMaximumPeriod
P1Y
CY2024Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
114600000
ptgx Noncurrent Contractual Maturities Minimum Period
NoncurrentContractualMaturitiesMinimumPeriod
P1Y
ptgx Noncurrent Contractual Maturities Maximum Period
NoncurrentContractualMaturitiesMaximumPeriod
P2Y
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0
CY2023 us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0
CY2024Q3 ptgx Credit Related Losses To Be Recognized
CreditRelatedLossesToBeRecognized
0
CY2024Q3 ptgx Prepaid Manufacturing Of Clinical Materials
PrepaidManufacturingOfClinicalMaterials
3775000
CY2023Q4 ptgx Prepaid Manufacturing Of Clinical Materials
PrepaidManufacturingOfClinicalMaterials
649000
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
217000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1410000
CY2024Q3 ptgx Prepaid Licenses
PrepaidLicenses
599000
CY2023Q4 ptgx Prepaid Licenses
PrepaidLicenses
529000
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
788000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1040000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2669000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
332000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8048000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3960000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9396000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7429000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6928000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6234000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2468000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1195000
CY2024Q3 ptgx Accrued Clinical And Research Related Expenses Current
AccruedClinicalAndResearchRelatedExpensesCurrent
11619000
CY2023Q4 ptgx Accrued Clinical And Research Related Expenses Current
AccruedClinicalAndResearchRelatedExpensesCurrent
11841000
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
8155000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
6786000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
846000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
632000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
119000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
99000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20739000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19358000
CY2024Q2 ptgx Operating Lease Improvement Allowance
OperatingLeaseImprovementAllowance
1800000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10500000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9835000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
954000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
45000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1141000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10855000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
10900000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1141000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y2M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y4M24D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.104
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
757000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
584000
us-gaap Operating Lease Cost
OperatingLeaseCost
2079000
us-gaap Operating Lease Cost
OperatingLeaseCost
1751000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
51000
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
35000
us-gaap Sublease Income
SubleaseIncome
34000
us-gaap Sublease Income
SubleaseIncome
114000
CY2024Q3 us-gaap Lease Cost
LeaseCost
757000
CY2023Q3 us-gaap Lease Cost
LeaseCost
549000
us-gaap Lease Cost
LeaseCost
2096000
us-gaap Lease Cost
LeaseCost
1637000
us-gaap Operating Lease Payments
OperatingLeasePayments
1385000
us-gaap Operating Lease Payments
OperatingLeasePayments
2047000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10511000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
223000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1121000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2786000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2881000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2983000
CY2024Q3 ptgx Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
2825000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
12819000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1919000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
10900000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2024Q2 ptgx Shares Authorized
SharesAuthorized
100000000
CY2024Q2 ptgx Shares Authorized
SharesAuthorized
190000000
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023Q3 ptgx Proceeds From Exercise Of Warrants In Exchange For Issuance Of Pre Funded Warrants
ProceedsFromExerciseOfWarrantsInExchangeForIssuanceOfPreFundedWarrants
34400000
CY2023Q3 ptgx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
44748
CY2023Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2705252
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023Q3 ptgx Minimum Percentage Of Common Stock Held By Investors For Not Exercise Of Warrants
MinimumPercentageOfCommonStockHeldByInvestorsForNotExerciseOfWarrants
0.0999
ptgx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
84992
CY2024Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2620260
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-400000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2620260
CY2024Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2620260
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-33210000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-34105000
us-gaap Net Income Loss
NetIncomeLoss
143514000
us-gaap Net Income Loss
NetIncomeLoss
-106290000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61767934
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59182899
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61311310
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55542543
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3300631
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61767934
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59182899
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64611941
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55542543
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.91
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.91
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9200000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3200000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8900000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8900000

Files In Submission

Name View Source Status
0001558370-24-014888-index-headers.html Edgar Link pending
0001558370-24-014888-index.html Edgar Link pending
0001558370-24-014888.txt Edgar Link pending
0001558370-24-014888-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ptgx-20240930.xsd Edgar Link pending
ptgx-20240930x10q.htm Edgar Link pending
ptgx-20240930x10q006.jpg Edgar Link pending
ptgx-20240930xex31d1.htm Edgar Link pending
ptgx-20240930xex31d2.htm Edgar Link pending
ptgx-20240930xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ptgx-20240930_cal.xml Edgar Link unprocessable
ptgx-20240930_def.xml Edgar Link unprocessable
ptgx-20240930_lab.xml Edgar Link unprocessable
ptgx-20240930_pre.xml Edgar Link unprocessable
ptgx-20240930x10q_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending